| Vol. 13.20 – 25 May, 2021 |
| |
|
|
| Investigators differentiated human induced pluripotent stem cells into the mesodermal and ectomesodermal lineages to prepare isogenic mesodermal cell-derived chondrocytes and neural crest cell-derived chondrocytes for comparative evaluation. [Science Advances] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists presented SFRP2 as a SOX2-antagonist with the capacity to induce a mesenchymal subtype transition in glioma cells located in vascular tumor areas, highlighting its role in glioblastoma tumor evolution and intratumoral heterogeneity. [Oncogene] |
|
|
|
| The authors examined intracellular levels of let-7f in 4T1 mammary carcinoma cells to test the hypothesis that let-7f released from human MSCs may be incorporated by tumor cells. [Cell Death & Disease] |
|
|
|
| Researchers investigated the effect of direct contact of prostate cancer (PCa) cells with MSCs on the stemness of PCa and its mechanisms. [Cell and Bioscience] |
|
|
|
| Investigators identified CG dinucleotides that become continuously hyper- or hypomethylated during long-term culture of MSCs and other cell types. [Communications Biology] |
|
|
|
| Scientists reported human inducible regulatory T cells (iTreg) co-cultured with bone marrow-derived MSCs during short-term ex vivo expansion enhanced the stability of iTreg FOXP3 expression and suppressive function in vitro and in vivo. [Scientific Reports] |
| |
|
|
| Researchers identified KDM4B as an epigenetic regulator of osteoclast differentiation. Knockdown of KDM4B significantly blocked the formation of tartrate-resistant acid phosphatase-positive multinucleated cells. [Bone Research] |
|
|
|
| Scientists combined new and previously published single-cell RNA-seq data from 98,015 single cells from a total of 66 gliomas to profile 19,331 individual macrophages. [Genome Medicine] |
|
|
|
| The authors identified milk fat globule-epidermal growth factor 8 (MFG-E8) as a key factor mediating chondrocyte senescence and macrophage polarization and revealed its role in the pathology of osteoarthritis. [Cell Death & Disease] |
|
|
|
| Investigators determined the clinical phenotype of TP53 mutations and p53 pathway alterations in patients with rhabdomyosarcoma and Ewing sarcoma treated with radiation. [British Journal of Cancer] |
|
|
|
| Researchers modulated miR-19b expression via mimics/inhibitors in bone marrow MSCs and via agomirs in mice to explore the effects of these changes on osteogenic factors, bone cell mineralization, and the healing status of modeled fractures. [Experimental & Molecular Medicine] |
|
|
|
| The authors established mouse models of CCl4-injured liver fibrosis (LF) and administered human placental MSCs (hPMSCs) at different stages of LF once a week for two weeks. The therapeutic effect of hPMSCs on LF was investigated, according to histopathological and blood biochemical analyses. [Stem Cell Research & Therapy] |
|
|
|
|
| Investigators summarize the regulatory effect of bone and bone-derived factors on energy metabolism and discuss directions for future research. [Bone Research] |
|
|
|
|
| Stemedica Cell Technologies, Inc. announced that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its MSC technologies in the treatment of COVID-19 and additional pulmonary conditions. [Stemedica Cell Technologies, Inc.] |
|
|
|
| Sorrento Therapeutics, Inc. announced receipt of clearance from the ANVISA to proceed with a Phase II Pivotal clinical trial of COVI-MSCâ„¢, an injectable infusion of MSCs, for the treatment of hospitalized COVID-19 patients suffering from acute respiratory distress syndrome. [Sorrento Therapeutics, Inc.] |
|
|
|
|
| September 7 – 11, 2022 Woods Hole, Massachusetts, United States |
|
|
|
|
|
| National University of Ireland Galway – Galway, Ireland |
|
|
|
| Louisiana State University – New Orleans, Louisiana, United States |
|
|
|
| Broad Institute – Cambridge, Massachusetts, United States |
|
|
|
| Hospital for Special Surgery – New York, New York, United States |
|
|
|
| Astellas Pharma – Westborough, Massachusetts, United States |
|
|
|
|